ALKERMES | ALKS - Interest Expense On Debt


ALKERMES reported $4.65M in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
ALKERMES USD 4.65M 1.35M Dec/2024
Amgen USD 653M 32M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Coherus Biosciences USD 2.15M 3.2M Mar/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 255M 1000K Dec/2025
Heron Therapeutics USD 500K 900K Sep/2024
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
J&J USD 18M 290M Sep/2025
Merck USD 412M 85M Dec/2025
Minerva Neurosciences USD 2.31M 60K Jun/2024
Nektar Therapeutics USD 6.02M 420K Sep/2024
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Otsuka Holdings JPY 2.21B 866M Dec/2025
Ovoca Bio EUR 7K 6K Jun/2022
Pfizer USD 711M 59M Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025